Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1985 2
1986 1
1987 1
1988 2
1989 4
1990 4
1991 1
1992 1
1994 2
1995 1
1996 4
1997 2
1998 1
1999 2
2000 4
2001 1
2002 4
2003 4
2004 4
2005 2
2006 3
2007 3
2008 1
2009 4
2010 4
2011 2
2012 6
2013 3
2014 5
2015 4
2016 4
2017 8
2018 5
2019 4
2020 3
2021 3
2022 5
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Reticulin Fibrosis of the Bone Marrow"
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow ret …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloprolifer …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations. Additional disease features include bone marrow …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloprolifer …
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J. Zahr AA, et al. Haematologica. 2016 Jun;101(6):660-71. doi: 10.3324/haematol.2015.141283. Haematologica. 2016. PMID: 27252511 Free PMC article. Review.
Bone marrow fibrosis is a central pathological feature and World Health Organization major diagnostic criterion of myelofibrosis. Although bone marrow fibrosis is seen in a variety of malignant and non-malignant disease states, the deposi …
Bone marrow fibrosis is a central pathological feature and World Health Organization major diagnostic criterion of myel …
Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy in B-acute lymphoblastic leukemia.
Anil J, Alnemri A, Lytle A, Lockhart B, Anil AE, Baumgartner M, Gebre K, McFerran J, Grupp SA, Rheingold SR, Pillai V. Anil J, et al. Am J Hematol. 2023 Dec;98(12):1888-1897. doi: 10.1002/ajh.27098. Epub 2023 Sep 18. Am J Hematol. 2023. PMID: 37718626
CD19 directed CAR T-cell therapy is used to treat relapsed/refractory B-cell acute lymphoblastic leukemia. The role of the pre-CAR bone marrow (BM) stromal microenvironment in determining response to CAR T-cell therapy has been understudied. ...NR showed significant …
CD19 directed CAR T-cell therapy is used to treat relapsed/refractory B-cell acute lymphoblastic leukemia. The role of the pre-CAR bone …
Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma.
Şeyhanlı A, Yavuz B, Akşit Z, Yüce Z, Özkal S, Altungöz O, Demirkan F, Alacacıoğlu İ, Özsan GH. Şeyhanlı A, et al. Turk J Haematol. 2022 Jun 1;39(2):109-116. doi: 10.4274/tjh.galenos.2021.2021.0325. Epub 2021 Nov 26. Turk J Haematol. 2022. PMID: 34823323 Free PMC article.
This study aimed to determine the cytogenetic characterization and bone marrow (BM) features of Turkish patients with MM. MATERIALS AND METHODS: Eighty-five MM patients were admitted to Dokuz Eylul University Hospital in Turkey. ...Fluorescence in situ hybridization …
This study aimed to determine the cytogenetic characterization and bone marrow (BM) features of Turkish patients with MM. MATE …
Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.
Pozdnyakova O, Hasserjian RP, Verstovsek S, Orazi A. Pozdnyakova O, et al. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):253-61. doi: 10.1016/j.clml.2014.11.002. Epub 2014 Nov 18. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25515354 Review.
Accurate diagnosis and classification of myeloproliferative neoplasms are prerequisites for appropriate risk-based therapy and should be based on an integrated approach following the World Health Organization guidelines that, in addition to clinical, molecular, and cytogenetic ev …
Accurate diagnosis and classification of myeloproliferative neoplasms are prerequisites for appropriate risk-based therapy and should be bas …
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.
Ryou H, Sirinukunwattana K, Aberdeen A, Grindstaff G, Stolz BJ, Byrne H, Harrington HA, Sousos N, Godfrey AL, Harrison CN, Psaila B, Mead AJ, Rees G, Turner GDH, Rittscher J, Royston D. Ryou H, et al. Leukemia. 2023 Feb;37(2):348-358. doi: 10.1038/s41375-022-01773-0. Epub 2022 Dec 5. Leukemia. 2023. PMID: 36470992 Free PMC article.
To improve the quantitation of reticulin fibrosis, we developed a machine learning approach using bone marrow trephine (BMT) samples (n = 107) from patients diagnosed with MPN or a reactive marrow. The resulting Continuous Indexing of Fibrosi …
To improve the quantitation of reticulin fibrosis, we developed a machine learning approach using bone marrow tr …
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Thiele J, Kvasnicka HM, Schmitt-Gräff A, Hülsemann R, Diehl V. Thiele J, et al. Histol Histopathol. 2004 Jan;19(1):239-50. doi: 10.14670/HH-19.239. Histol Histopathol. 2004. PMID: 14702192 Review.
In chronic myeloproliferative disorders (CMPDs) a conflict of opinion exists regarding therapy-induced bone marrow (BM) changes and the evolution of myelofibrosis during the lengthy course of the disease. ...Most conspicuous was a gelatinous edema showing a tendency …
In chronic myeloproliferative disorders (CMPDs) a conflict of opinion exists regarding therapy-induced bone marrow (BM) change …
The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.
Mudireddy M, Barraco D, Hanson CA, Pardanani A, Gangat N, Tefferi A. Mudireddy M, et al. Am J Hematol. 2017 May;92(5):454-459. doi: 10.1002/ajh.24689. Epub 2017 Mar 20. Am J Hematol. 2017. PMID: 28211153 Free article.
In the current study of 183 consecutive patients with WHO-defined ET, the presence of grade 1 bone marrow (BM) fibrosis did not affect presenting clinical or laboratory features; in contrast, increased serum LDH at diagnosis was associated with leukocytosis ( …
In the current study of 183 consecutive patients with WHO-defined ET, the presence of grade 1 bone marrow (BM) fibrosis …
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
Tanrikulu Simsek E, Eskazan AE, Cengiz M, Ar MC, Ekizoglu S, Salihoglu A, Gulturk E, Elverdi T, Ongoren Aydin S, Senem Demiroz A, Buyru AN, Baslar Z, Ozbek U, Ferhanoglu B, Aydin Y, Tuzuner N, Soysal T. Tanrikulu Simsek E, et al. J Clin Pathol. 2016 Sep;69(9):810-6. doi: 10.1136/jclinpath-2015-203320. Epub 2016 Jan 25. J Clin Pathol. 2016. PMID: 26811428
AIMS: Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. ...
AIMS: Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with c …
112 results